A

new federal effort is underway to keep biopharmaceutical manufacturing stateside — and scale up the production of complex biological drugs.

A new high-tech trade group, dubbed NIIMBL — the pithy shorthand for the National Institute for Innovation in Manufacturing Biopharmaceuticals — on Friday received $70 million from the Department of Commerce. On top of that, NIIMBL will be getting another $129 million from a public-private consortium of 150 companies, academic institutions, and nonprofits, as well as 25 states.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine